Targeting the Biopterines Reduction Pathway for the Development of New Drugs against Leishmaniasis and Trypanosomiasis. Premise. The discovery of new drugs in the field of neglected diseases represents a major task within the whole drug discovery area. Why is the number of drugs in the discovery pipelines so low? Why are we still using so many old drugs? Why is it more difficult to promote a drug candidate to the clinical use in the area of neglected disease? One of the answers may be the requirements of the drug profile in this area that show more constraints than in any other area. In fact the ideal drug should be very specific for the pathogen, easy to be synthetically prepared, stable at room temperature, orally available, one dose for daily use, extremely low cost and easy to combine with other existing drugs to delay resistance development. Apart from the mentioned intrinsic features, the highest barrier at the moment is due to the low level of critical mass working in the area and the low grant level. The number of groups that work on parasitic diseases is limited due to the level of financing in comparison with other therapeutic area. This has a statistical relevance on the output quality and on the pipeline filing 1. A drug discovery case in the preclinical phase within the folate pathway of the Kintetoplastidae parasites will be presented.
|Data di pubblicazione:||2012|
|Titolo:||ESMEC invited lecture. Targeting the Biopterines Reduction Pathway for the Development of New Drugs against Leishmaniasis and Trypanosomiasis.|
|Autori:||Costi, Maria Paola|
|Appare nelle tipologie:||Altro|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris